Rubitecan
- Generic Name
- Rubitecan
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15N3O6
- CAS Number
- 91421-42-0
- Unique Ingredient Identifier
- H19C446XXB
- Indication
Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified).
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005872
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 21
- Registration Number
- NCT00006026
- Locations
- 🇫🇷
Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France
🇮🇹Azienda Ospedaliera di Padova, Padova (Padua), Italy
🇫🇷Centre Henri Becquerel, Rouen, France
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005869
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005877
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2012-09-26
- Target Recruit Count
- 44
- Registration Number
- NCT00006047
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005876
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2003-05-22
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 38
- Registration Number
- NCT00006082
- Locations
- 🇫🇷
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00006267
Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 51
- Registration Number
- NCT00006230
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇨🇭Ospedale San Giovanni, Bellinzona, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.